Status:
COMPLETED
Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients
Lead Sponsor:
Muhammad Aamir Latif
Conditions:
Thalassemia
Eligibility:
All Genders
2-5 years
Phase:
NA
Brief Summary
This study aimed to determine the safety and efficacy of thalidomide in multi-transfused thalassemic children.
Detailed Description
Given the significant burden of transfusion dependency, an effective and safe inducer is needed that could improve quality of life and reduce the healthcare costs associated with frequent transfusions...
Eligibility Criteria
Inclusion
- Children of both genders
- Aged 2-5 years
- With transfusion-dependent thalassemia (TDT)
- Whose parents/guardians showed willingness to adhere to follow-up visits
Exclusion
- Children with uncontrolled infections
- Significant hepatic or renal dysfunction
- Malignancy
- Known contraindications to thalidomide
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT06888232
Start Date
August 1 2023
End Date
December 31 2024
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital & Institute of Child Health
Multan, Punjab Province, Pakistan, 66000